浸潤膀胱癌に対する根治的膀胱全摘除術後の補助化学療法について—Doxorubicin hydrochlorideとCarboquoneの併用

ADJUVANT CHEMOTHERAPY FOR INVASIVE BLADDER CANCER FOLLOWING RADICAL CYSTECTOMY WITH DOXORUBICIN HYDROCHLORIDE AND CARBOQUONE

　1982年から1985年の間で，骨盤内リンパ郭清を含む根治的膀胱全摘除術を行つた浸潤膀胱癌（PT3およびPT4）12例に対して，　doxorubicin hydrochloride　とcarboquoneによる術後の補助化学療法を行つた。男性8例および女性4例で，年齢は57歳から75歳（平均66.6歳）であつた。郭清リンパ節に転移のなかつた6例は，すべて癌再発なく術後25ないし40カ月（平均33.3カ月）で生存していた。郭清リンパ節に転移のあつた6例では，5例に癌再発がみられ，このうち4例は術後11ないし26カ月で癌死した。リンパ節転移例の転帰は極めて悪く，より有効な補助療法が必要とされるものであつた。

From 1982 to 1985, twelve patients undergoing radical cystectomy with pelvic lymph node dissec-tion in pathologic stage PT 3 and PT 4, received adjuvant chemotherapy consisted of doxorubicin hydrochloride and carboquone. There were 8 men and 4 women between 57 and 75 years old (median age 66.6 years). Six patients without nodal metastasis were all alive with no evidence of disease for an average 33. 3 months, with a range of 25 to 40 months. Among six patients with nodal metastasis, 4 patients died of cancer progression between 11 and 26 months postoperatively, and one patient was alive with cancer recurrence 10 months after surgery.